Unity raises $55M series C

Unity Biotechnology Inc. (San Francisco, Calif.) raised $55 million in a series C round on March 19. New investors EcoR1 Capital Fund, 6 Dimensions Capital and Altitude Life Sciences Ventures participated, as did existing investors Fidelity, Baillie Gifford, Partner Fund Management, Pivotal Alpha Ltd., Invus Opportunities, Arch Venture Partners, Venrock, Founders Fund and the Longevity Fund.

Unity's lead candidates target senescent cells to treat age-related diseases (see BioCentury, Oct. 31, 2016)...